Business Description
CytoMed Therapeutics Ltd
ISIN : SGXZ17669631
Description
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 15.15 | |||||
Equity-to-Asset | 0.93 | |||||
Debt-to-Equity | 0.04 | |||||
Debt-to-EBITDA | -0.16 | |||||
Piotroski F-Score | 4/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -35.5 | |||||
3-Year EPS without NRI Growth Rate | -26.6 | |||||
3-Year FCF Growth Rate | -48.1 | |||||
3-Year Book Growth Rate | 181 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 61.54 | |||||
9-Day RSI | 56.85 | |||||
14-Day RSI | 55.54 | |||||
6-1 Month Momentum % | 17.39 | |||||
12-1 Month Momentum % | -33.33 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 21.52 | |||||
Quick Ratio | 21.52 | |||||
Cash Ratio | 18.07 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1.8 | |||||
Shareholder Yield % | 5.2 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -26.66 | |||||
ROA % | -24.79 | |||||
ROIC % | -122.17 | |||||
ROC (Joel Greenblatt) % | -107.44 | |||||
ROCE % | -25.57 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 3.61 | |||||
Price-to-Tangible-Book | 3.63 | |||||
EV-to-EBIT | -9.95 | |||||
EV-to-EBITDA | -11.22 | |||||
EV-to-FCF | -9.57 | |||||
Price-to-Net-Current-Asset-Value | 5.19 | |||||
Price-to-Net-Cash | 6.41 | |||||
Earnings Yield (Greenblatt) % | -10.05 | |||||
FCF Yield % | -8.72 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
CytoMed Therapeutics Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | -0.18 | ||
Beta | 0 | ||
Volatility % | 79.59 | ||
14-Day RSI | 55.54 | ||
14-Day ATR (€) | 0.107152 | ||
20-Day SMA (€) | 2.0855 | ||
12-1 Month Momentum % | -33.33 | ||
52-Week Range (€) | 1.25 - 3.82 | ||
Shares Outstanding (Mil) | 11.54 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
CytoMed Therapeutics Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
CytoMed Therapeutics Ltd Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
CytoMed Therapeutics Ltd Frequently Asked Questions
What is CytoMed Therapeutics Ltd(FRA:F98)'s stock price today?
When is next earnings date of CytoMed Therapeutics Ltd(FRA:F98)?
Does CytoMed Therapeutics Ltd(FRA:F98) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |